article Open AccessTop 1% cited

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

British Journal of Dermatology · 2017 · Vol. 178(5) · pp. 1083–1101

Marjolein de Bruin‐Weller✉(University Medical Center Utrecht)Diamant Thaçi(University of Lübeck)Catherine Smith(St. John's Hospital)Kristian Reich(Dermatologikum Hamburg)Michael J. Cork(University of Sheffield)Allen Radin(Regeneron (United States))Q. Zhang(Regeneron (United States))Bolanle Akinlade(Regeneron (United States))A. Gadkari(Regeneron (United States))Laurent Eckert(Sanofi (France))Thomas Hultsch(AVEO Oncology (United States))Z. Chen(Regeneron (United States))Gianluca Pirozzi(Sanofi (United States))Neil M.H. Graham(Regeneron (United States))Brad Shumel(Regeneron (United States))

View via DOI Full-text PDF

Abstract

Dupilumab + TCS significantly improved signs and symptoms of atopic dermatitis and QoL in adults with a history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.

Dermatology and Skin Diseases Allergic Rhinitis and Sensitization Asthma and respiratory diseasesDupilumabMedicineAtopic dermatitisCiclosporinEczema Area and Severity IndexConcomitantPlaceboAdverse effectRandomized controlled trialInternal medicine

MeSH terms

Young AdultAdministration, CutaneousAdolescentAdrenal Cortex HormonesAdultAgedAntibodies, MonoclonalDermatitis, AtopicDermatologic AgentsDouble-Blind MethodDrug Administration ScheduleDrug HypersensitivityDrug Therapy, CombinationFemaleHumans